Clinical trials: Central Nervous System Vasculitis
Giant Cell Arteritis
Evaluation of PET/CT of Cephalic Arteries for the Diagnosis of Giant Cell Arteritis
Giant cell arteritis (GCA) is the most common vasculitis in adults. The diagnosis of GCA is evoked by the association of clinical signs and biological anomalies (inflammatory syndrome) in patients over 50 years of age.
- Trial name
- Cervico-TEP et (NCT05246540)
- Testing
- Data collection
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Rheumatic Diseases, Lupus Erythematosus, Systemic
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Background: Rheumatic diseases can affect the joints, ligaments, tendons, bones, muscles, and skin. They can also cause inflammation, damage body tissues, and change nerve signals in the brain.
- Conditions
- Rheumatic Diseases, Lupus Erythematosus, Systemic, Lupus Vasculitis, Central Nervous System, Arthritis
- Trial name
- NCT07829497
- Testing
- Bedside quantitative sensory testing
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Takayasu's Arteritis, Giant Cell Arteritis
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Background: Vasculitis is a group of diseases that inflame and damage blood vessels and tissue. It can cause many medical problems. Few tests can diagnose the disease, and none can reliably predict a relapse.
- Conditions
- Takayasu's Arteritis, Giant Cell Arteritis, Polyarteritis Nodosa, Relapsing Polychondritis
- Trial name
- NCT02257866
- Where
- United States
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Giant Cell Arteritis
Association of Ultrasonographic Temporal Artery Lesions and Relapse in Patients With Giant Cell Arteritis
Ultrasound evaluation of the temporal and axillary arteries is currently well recognized in the field of giant cell arteritis (GCA), a disease primarily affecting medium- and large-caliber vessels.
- Trial name
- ALERT (NCT06894602)
- Where
- 2 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Brest
Giant Cell Arteritis (GCA)
Bosentan in the Treatment of Giant Cell Arteritis
The purpose of this study is to determine whether a treatment with 3 months of bosentan associated to standard therapy might be superior to glucocorticoids alone in term of failure free survival at 12 months
- Trial name
- BOSICART (NCT06957002)
- Testing
- Bosentan, Glucocorticoids
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Wegener's Granulomatosis, Churg-Strauss Syndrome
RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides
The purpose of this study is to compare a 2 immunosuppressant regimen for the treatment of relapsing or refractory necrotizing antineutrophil cytoplasmic antibody (ANCA) associated vasculitides.
- Conditions
- Wegener's Granulomatosis, Churg-Strauss Syndrome, Microscopic Polyangiitis
- Trial name
- NCT00307593
- Testing
- Infliximab, Rituximab
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Giant Cell Arteritis
A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis
The primary purpose of this study is to evaluate the efficacy of guselkumab compared to placebo, in combination with a 26-week glucocorticoid (GC) taper regimen, in adult participants with new-onset or relapsing giant cell…
- Trial name
- THEIA (NCT04633447)
- Testing
- Guselkumab
- Where
- 30 sites in United States, Belgium and 7 more
- Volunteers
- 53 people
- Sponsor
- Janssen Research & Development, LLC
Giant Cell Arteritis
Hydroxychloroquine in Giant Cell Arteritis
Cortico-dependence is frequent in giant cell arteritis patients, and no drugs has proved its ability to prevent corticodependence.
- Trial name
- NCT00430807
- Where
- 23 sites in France
- Volunteers
- 75 people
- Sponsor
- University Hospital, Toulouse
Behcet's Disease, Churg-Strauss Syndrome
VCRC Patient Contact Registry Patient-Reported Data Validation Study
The purpose of this study is to provide validation of patient-reported data in the VCRC Patient Contact Registry by comparing patient-reported data with data provided by the physician who is the primary provider caring for the…
- Conditions
- Behcet's Disease, Churg-Strauss Syndrome, Giant Cell Arteritis, Wegener Granulomatosis
- Trial name
- NCT02190942
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- University of South Florida
Behcet's Disease, Churg-Strauss Syndrome
Educational Needs of Patients With Systemic Vasculitis
A cross-sectional study design and online questionnaire was used to assess the informational needs of patients with several different types of systemic vasculitis.
- Conditions
- Behcet's Disease, Churg-Strauss Syndrome, Vasculitis, Central Nervous System, Giant Cell Arteritis
- Trial name
- NCT02190929
- Where
- United States
- Volunteers
- 386 people
- Sponsor
- University of South Florida
Optic Neuritis, Transverse Myelitis
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
The Swiss-Ped-IBrainD is a national patient registry that collects information on diagnosis, symptoms, treatment, and follow-up of pediatric patients with an inflammatory brain disease in Switzerland.
- Conditions
- Optic Neuritis, Transverse Myelitis, Acute Disseminated Encephalomyelitis, Multiple Sclerosis
- Trial name
- NCT05017142
- Where
- 13 sites in Switzerland
- Volunteers
- 500 people
- Sponsor
- University of Bern
Adrenal Insufficiency, Polymyalgia Rheumatica (PMR)
Hydrocortisone and Placebo in Patients With Symptoms of Adrenal Insufficiency After Cessation of Glucocorticoid Treatment
Cortisol, a glucocorticoid (GC) hormone secreted from the adrenal glands, is essential for survival. Cortisol also possesses anti-inflammatory actions and GC formulations (prednisolone) are used to treat many inflammatory…
- Conditions
- Adrenal Insufficiency, Polymyalgia Rheumatica (PMR), Giant Cell Arteritis (GCA)
- Trial name
- REPLACE (NCT05193396)
- Testing
- Hydrocortisone
- Where
- 3 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Marianne Andersen
Rheumatoid Arthritis, Polymyalgia Rheumatica
Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.
The purpose of this study is to determine wich treatment is the most effective in prevention of glucocorticoid-induced osteoporosis in patients with rheumatic diseases.
- Conditions
- Rheumatoid Arthritis, Polymyalgia Rheumatica, Giant Cell Arteritis, Polymyositis
- Trial name
- NCT00138983
- Testing
- Alendronate versus alfacalcidol (1-alpha OH vitamin D)
- Where
- Netherlands
- Volunteers
- 200 people
- Sponsor
- UMC Utrecht
Giant Cell Arteritis, Optic Ischaemic Neuropathy
Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA
AION is the main cause of blindness in patients with GCA. High dose steroid is the reference treatment of this condition, but medical unmet need remains.
- Trial name
- TOCIAION (NCT04239196)
- Testing
- tocilizumab and IV steroids combination, IV steroids combination alone
- Where
- 10 sites in France
- Volunteers
- 58 people
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
ANCA-associated Primary Necrotizing Vasculitides
Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides
The purpose of this study is to assess whether rosuvastatin could reduce the subclinical markers of atherosclerosis and the incidence of major cardiovascular events in patients with primary necrotizing vasculitides.
- Trial name
- STATVAS (NCT02117453)
- Testing
- Rosuvastatin
- Where
- France
- Volunteers
- 121 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA)
Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA
The purpose of this study is to investigate the safety and tolerability of two dose regimens of IFX-1 as add-on to standard of care (SOC) in subjects with GPA and MPA compared with placebo.
- Trial name
- NCT03712345
- Testing
- IFX-1 low dose, IFX-1 high dose
- Where
- 38 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- InflaRx GmbH
Giant Cell Arteritis, Polymyalgia Rheumatic (PMR)
Giant Cell Arteritis - Ways to Precision Medicine
Long-term follow-up of aortal adverse events, as well as glucocortioid-associated adverse events in patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA).
- Trial name
- NCT07084480
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Wuerzburg University Hospital
Vasculitis, Systemic Lupus Erythematosus
Predictors of Mortality in Patients With Autoimmune Diseases Admitted to the Intensive Care Unit
Autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, myositis, or anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, may affect multiple organ systems.
- Conditions
- Vasculitis, Systemic Lupus Erythematosus, Myositis
- Trial name
- NCT04022655
- Testing
- ICU Care
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University of Göttingen
Giant Cell Arteritis, Takayasu Arteritis
PET Imaging of Giant Cell and Takayasu Arteritis
While 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging is often included in the diagnostic work-up of patients with large-vessel vasculitis (LVV), 18F-FDG lacks specificity for inflammatory cells and has…
- Trial name
- PITA (NCT04071691)
- Testing
- PET-MRI
- Where
- 2 sites in United Kingdom
- Volunteers
- 27 people
- Sponsor
- University of Cambridge
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis
Low-dose Glucocorticoid Vasculitis Induction Study
Previous reports suggested conventional immunosuppressants such as cyclophosphamide could not reduce glucocorticoid dose in remission induction in ANCA-associated vasculitis because of lower remission rate and higher relapse…
- Conditions
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis, Wegener Granulomatosis
- Trial name
- LoVAS (NCT02198248)
- Testing
- Rituximab, Glucocorticoids
- Where
- 17 sites in Japan
- Volunteers
- 140 people
- Sponsor
- Chiba University